Literature DB >> 3744947

In vitro binding of 14C-misonidazole to hepatocytes and hepatoma cells.

D J Van Os-Corby, J D Chapman.   

Abstract

The binding rate of 14C-Misonidazole was determined for freshly isolated mouse hepatocytes, mouse hepatoma cells, EMT-6 tumor cells, and V79 Chinese hamster lung fibroblasts. At 10 microM drug concentration, the four different cell lines bound 14C-Misonidazole at rates of 12.4, 29.9, 51.6, and 13.5 pmoles/10(6) cells/hr, respectively. This relative order of binding was observed over a drug concentration range of 10-100 microM. These data indicate that in extreme hypoxia, mouse hepatocytes do not bind 14C-Misonidazole at a uniquely high rate in vitro, compared to other normal and tumor cell lines. This observation suggests that the increased binding to liver in vivo observed by other investigators is due to the liver existing at a reduced oxygen tension, compared to other normal tissues.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3744947     DOI: 10.1016/0360-3016(86)90270-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Conversion of xanthine dehydrogenase to xanthine oxidase as a possible marker for hypoxia in tumours and normal tissues.

Authors:  R F Anderson; K B Patel; K Reghebi; S A Hill
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

2.  Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells.

Authors:  M B Parliament; L I Wiebe; A J Franko
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

3.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.

Authors:  G E Arteel; R G Thurman; J M Yates; J A Raleigh
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

4.  Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.

Authors:  I J Stratford; G E Adams; J Godden; J Nolan; N Howells; N Timpson
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.